
 Scientific claim: Ribosomopathies have a high degree of cell and tissue specific pathology. 
 Participant Dynamics: Beneficiary vs. Authority 
 Contextual Arena: The Deliberative Arena (goal: to make a strategic choice) 
 Interaction Trigger: A Recent Discovery (new, urgent data) 
 Dialogue Objective: To Define the Disagreement (map out points of conflict) 
``` 
Dr. Peters: Good afternoon, everyone. As you know, we've just received new data regarding ribosomopathies and their impact on cellular pathology. It's quite intriguing.

Dr. Lopez: Indeed, Dr. Peters. The revelation that these disorders exhibit a high degree of cell and tissue-specific pathology can significantly shift our understanding.

Dr. Peters: Precisely. This specificity raises questions about targeting treatments effectively. We need to decide on the best strategic approach to leverage this information.

Dr. Singh: But hold on, Dr. Peters. This specificity might complicate things. Doesn't it suggest that a one-size-fits-all treatment won't work?

Dr. Peters: That's exactly the point of contention, Dr. Singh. While precision treatments can be more effective, they also require more resources and are more complex to develop.

Dr. Lopez: But isn't that complexity worth it if it means better patient outcomes? We can't ignore the potential benefits of personalized therapy.

Dr. Singh: True, Dr. Lopez. Yet, we must consider the practicality. Can our current infrastructure even support such personalized approaches on a large scale?

Dr. Peters: And this is where we seem to diverge. Do we invest heavily now in a potentially groundbreaking approach? Or do we continue refining broader treatments that are already in place?

Dr. Lopez: If we're aiming for long-term progress, personalized approaches could revolutionize treatment. But Dr. Singh’s point about infrastructure is valid. 

Dr. Singh: Not to mention the funding. These new treatment paths could drain resources from other critical research areas.

Dr. Peters: So, we agree that the new data is crucial but are at odds about the implementation strategy. Should we convene a committee to explore potential pathways?

Dr. Lopez: I think that’s a sound initial step. A committee can help map out the feasibility and define the scope for each approach.

Dr. Singh: Agreed. Let's ensure we have diverse expertise on that committee to cover all angles.

Dr. Peters: Excellent. Let's move forward with that plan. Thank you, everyone. Your insights are invaluable.
```